Pharmacogenomics of Warfarin in Hispanics and Latinos

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Arizona

About this trial

Warfarin is a commonly used blood thinner to treat and prevent blood clots. It is important to take the right dose of warfarin because too much can increase the risk of bleeding and too little can increase the risk of blood clots. This is why patients are closely monitored especially when they begin warfarin therapy. When clinicians prescribe warfarin, they have to consider different factors such as patient's age, body size, diet, and other medications that can interact with warfarin.

Certain genes have also been found to affect warfarin dose. Individuals have variations in these genes, which can help explain why some patients need higher dose and others require less. These factors have been used to better predict a patient's warfarin dose requirement. However, these predictions were created based on Caucasian populations and they may not be accurate in predicting a safe warfarin dose if a patient is not Caucasian. This study aims to identify new genetic variation that affects warfarin dosing in Hispanic and Latino populations and try to better predict a Hispanic or Latino patient's warfarin dose requirement.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

At least 18 years of age

Ability to give informed consent

Therapeutic INR for at least 2 consecutive clinic visits

Self-identifies as Hispanic or Latino

Disqualifiers

Less than 18 years old

Unable to give informed consent

Severe hepatic impairment

Trial population

The study population will be Hispanic and Latino patients on stable doses of warfarin therapy.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Mouthwash sample

    Procedure/Surgery

    A one time mouthwash sample will be performed.

  • Blood Draw

    Procedure/Surgery

    Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Stable warfarin dose

Dose of warfarin required to maintain stable INR for at least 2 consecutive clinic visits.

Time frame
At time of enrollment

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.